Jerry McLaughlin

New Capabilities

Leading company through its first clinical trial and $80M Series D raise

In 2006, Shinya Yamanaka showed that four genes could rewind an adult cell all the way back to an embryonic-like state. Twenty years later, a stripped-down version of that technique is being injected into human eyes for the first time. Life Biosciences, a Boston biotech co-founded by Harvard aging researcher David Sinclair, has begun dosing glaucoma patients with ER-100, a gene therapy that delivers three of Yamanaka's four reprogramming factors to retinal cells — with a built-in off switch controlled by the common antibiotic doxycycline.

Updated 3 hours ago